High-sensitivity cardiac troponin and the diagnosis of myocardial infarction in patients with kidney impairment
Peter J Gallacher,Eve Miller-Hodges,Anoop S V Shah,Tariq E Farrah,Nynke Halbesma,James P Blackmur,Andrew R Chapman,Philip D Adamson,Atul Anand,Fiona E Strachan,Amy V Ferry,Kuan Ken Lee,Colin Berry,Iain Findlay,Anne Cruickshank,Alan Reid,Alasdair Gray,Paul O Collinson,Fred S Apple,David A McAllister,Donogh Maguire,Keith A A Fox,Catriona Keerie,Christopher J Weir,David E Newby,Nicholas L Mills,Neeraj Dhaun,High-STEACS Investigators,Christopher Tuck,Anda Bularga,Ryan Wereski,Matthew T H Lowry,Caelan Taggart,Dennis Sandeman,Catherine L Stables,Catalina A Vallejos,Athanasios Tsanas,Lucy Marshall,Stacey D Stewart,Takeshi Fujisawa,Jean McPherson,Lynn McKinlay,Simon Walker,Ian Ford,Anne Cruikshank,Shannon Amoils,Jennifer Stevens,John Norrie,Jack P M Andrews,Alastair Moss,Mohamed S Anwar,John Hung,Jonathan Malo,Colin M Fischbacher,Bernard L Croal,Stephen J Leslie,Richard A Parker,Allan Walker,Ronnie Harkess,Tony Wackett,Christopher Weir,Roma Armstrong,Laura Stirling,Claire MacDonald,Imran Sadat,Frank Finlay,Heather Charles,Pamela Linksted,Stephen Young,Bill Alexander,Chris Duncan
DOI: https://doi.org/10.1016/j.kint.2022.02.019
Abstract:The benefit and utility of high-sensitivity cardiac troponin (hs-cTn) in the diagnosis of myocardial infarction in patients with kidney impairment is unclear. Here, we describe implementation of hs-cTnI testing on the diagnosis, management, and outcomes of myocardial infarction in patients with and without kidney impairment. Consecutive patients with suspected acute coronary syndrome enrolled in a stepped-wedge, cluster-randomized controlled trial were included in this pre-specified secondary analysis. Kidney impairment was defined as an eGFR under 60mL/min/1.73m2. The index diagnosis and primary outcome of type 1 and type 4b myocardial infarction or cardiovascular death at one year were compared in patients with and without kidney impairment following implementation of hs-cTnI assay with 99th centile sex-specific diagnostic thresholds. Serum creatinine concentrations were available in 46,927 patients (mean age 61 years; 47% women), of whom 9,080 (19%) had kidney impairment. hs-cTnIs were over 99th centile in 46% and 16% of patients with and without kidney impairment. Implementation increased the diagnosis of type 1 infarction from 12.4% to 17.8%, and from 7.5% to 9.4% in patients with and without kidney impairment (both significant). Patients with kidney impairment and type 1 myocardial infarction were less likely to undergo coronary revascularization (26% versus 53%) or receive dual anti-platelets (40% versus 68%) than those without kidney impairment, and this did not change post-implementation. In patients with hs-cTnI above the 99th centile, the primary outcome occurred twice as often in those with kidney impairment compared to those without (24% versus 12%, hazard ratio 1.53, 95% confidence interval 1.31 to 1.78). Thus, hs-cTnI testing increased the identification of myocardial injury and infarction but failed to address disparities in management and outcomes between those with and without kidney impairment.